Rescuing stroke drug development: How NIH is leading the charge

Every 3 minutes and 14 seconds, someone dies of stroke in the U.S., yet drug developers largely abandoned the indication years ago.

A string of clinical trial failures contributed to the retreat, which has led industry to virtually ignore the second-leading cause of death worldwide. It’s a massive unmet need that should be a major market opportunity. Factors behind the failures ranged from biological unknowns to poor preclinical animal models to the difficulties of executing human stroke trials...